Will Alten Be A Significant Clinical Trials CRO?

/ August 31, 2021

ER&D services largest pure-play, Alten, has ambitions as a clinical trials contract research organization (CRO). During Q2 2021, the company completed the acquisition of Cmed. Cmed, a clinical trial CRO based in the UK. It is a small firm with EUR 20m in revenues and 180 consultants. It has specialized in oncology, immuno-oncology, cell therapy, and rare disease.

Charles River Gains Large Molecules Expertise, Targeting Biotechs

/ January 13, 2021

Charles River Labs (CRL) will gain further expertise for biotechs. The company is to acquire San Francisco-based Distributed Bio, a large molecules specialist firm focusing on antibody discovery. Distributed Bio will become part of CRL’s core R&D business, Discovery & Safety Assessment.

NNIT Shows A Path to Growth in Pharma

/ November 11, 2020

We rarely talked about Denmark-based NNIT. The company is the former IT captive of Danish pharmaceutical firm Novo Nordisk, thus the name NNIT, which stands for Novo Nordisk IT.

Dassault Sytems Lowers its Q1 2020 Guidance: Read-Throughs for the ER&D Service Industry

/ April 7, 2020

Dassault Systems lowered it Q1 2020: the company is now expecting revenue growth in the range of 14%-17%, down from a 20-23% guidance (that includes the acquisition of Medidata). The company has suffered from weaker than expected new license and services revenues. Meanwhile, revenues of Medidata were on a “momentum and license renewals were up too.

Accenture Acquires Two Firms in October YTD

/ October 20, 2019

It has been almost three years since Accenture launched Industry X.0, and we estimate that Accenture acquired nine competitors in these 36 months. The pace is accelerating with Accenture having five competitors in 2019, YTD.

An introduction to Evotec

/ September 1, 2019

Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org

Introducing our pharma R&D research

/ July 3, 2019

We have highlighted several times that the pharmaceutical sector represents ~25% of all R&D spending globally, more than automotive and aerospace. Still, very few vendors service pharma clients, and when they do, they provide manufacturing-related engineering services but never target R&D departments.